The composite drug components include: (a) enhanced S-100 protein antibody active form, (b) enhanced tissue antibody active form, (c) The enhanced antibody active form of TNF-a provides a number of specific conditions and variants 3: demand 2 of the composite drug composition, which is characterized by the flat form. 11. Claim 10: the combined pharmaceutical component of claim 1, characterized in that the active form of enhancing antibody to histamine is a single clone antibody,Polychlorinated diphenyl or natural 113. Claim 12: the compound pharmaceutical ingredient of claim 1, which is characterized in that the enhanced active form of the S-100 protein antibody is a monoclonal, polychlorinated or natural antibody. 113. Claim 14: the compound pharmaceutical ingredient of claim 1, which is characterized in that the enhanced active form from an antibody to TNF-a is a single, polychlorinated biphenyls or natural antibody. Claim 22: pharmaceutical ingredients for the treatment of patients with gastrointestinal diseases or functional causes,It is characterized by the provision of (a) enhanced antibody to histamine active forms, (b) enhanced protein antibody S-100 and (c) enhanced antibody to TNF-a active forms, each of which is prepared by continuous repeated dilution and multiple oscillations. Each of the solutions obtained through homeopathy techniques is then combined with an enhanced solution, or a hybrid or otherwise impregnated carrier is combined with such a solution, or the solution is separated. Claim 27: pharmaceutical ingredients in claim 22,It is characterized by a mixture of C12, C30 and C20 homeodiluents in each of the enhanced antibody active forms.Composición farmacéutica de combinación que comprende: a) una forma activada potenciada de un anticuerpo a una Proteína S-100, b) una forma activada potenciada de un anticuerpo a histamina, y c) una forma activada potenciada de un anticuerpo a TNF-a. Se proporcionan varias materializaciones y variantes.Reivind
